Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
Status:
Completed
Trial end date:
2016-09-30
Target enrollment:
Participant gender:
Summary
This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in
patients with advanced, previously treated tumors. 765IGF-MTX is administered as an IV
infusion over 1 hour on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease
progression, unacceptable toxicity, or patient refusal. Assessment of response will be
confirmed with imaging studies performed at the end of cycle 2 +/- 7 days, and every 2 weeks
thereafter.
Phase:
Phase 1
Details
Lead Sponsor:
IGF Oncology, LLC University of Illinois at Chicago